The Japan Atherosclerosis Society guidelines recommend intensive lipid-lowering therapy for secondary prevention in patients with coronary artery disease, particularly those with high-risk comorbidities.
These guidelines provide comprehensive recommendations for the secondary prevention of atherosclerotic cardiovascular diseases in Japanese patients with coronary artery disease.
Epidemiological and interventional studies conducted in Western countries and the results of a metaanalysis have revealed that the incidence of cardiovascular events in patients with coronary artery disease (CAD) is higher than that observed in primary prevention patients. In Japan, the incidence of cardiovascular events in patients who receive dietary therapy was found to be 2.1/1,000 person-years in the MEGA study In contrast, the incidence of cardiovascular events in patients with CAD was found to be 4.5/1,000 person-years in the J-LIT study 3) and 6.8/1,000 person-years in the JELIS study 4) . The JCAD 5) and CREDO-Kyoto studies 6) , registry studies of patients with CAD, both reported a high incidence of cardiovascular events of 15/1,000 person-years. Moreover, among patients with CAD, those with the conditions listed in Table It has been reported that such patients have a clearly higher incidence of coronary events, even when the LDLcholesterol (LDL-C) level is managed to the same extent as in patients without complications.
Teramoto et al. (Mon,) conducted a review in Coronary Artery Disease. Lipid-lowering therapy (Statins) was evaluated. The Japan Atherosclerosis Society guidelines recommend intensive lipid-lowering therapy for secondary prevention in patients with coronary artery disease, particularly those with high-risk comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: